Pembrolizumab dMMR Endometrial Cancer PFS Benefit Confirmed in KEYNOTE-C93 Trial

Pembrolizumab dMMR Endometrial Cancer PFS data show that pembrolizumab delivered a statistically significant and clinically meaningful progression-free survival benefit compared with platinum-based chemotherapy in patients with mismatch repair deficient advanced or recurrent endometrial cancer. This marks the first Phase 3 evidence of a PD-1 inhibitor working as monotherapy in the frontline setting for this group. Overall survival displayed an early positive trend but data remain immature, while response rates and safety findings stayed consistent with earlier experience.

KEYNOTE-C93 Design and Endpoints

The KEYNOTE-C93 study used a randomized open-label design comparing pembrolizumab every six weeks with carboplatin plus paclitaxel every three weeks. Patients had no prior systemic chemotherapy or experienced late recurrence after adjuvant therapy. Dual primary endpoints focused on PFS by blinded independent central review per RECIST 1.1 and overall survival to measure both disease control and longer-term outcomes.

Response and Safety Data

Pembrolizumab dMMR Endometrial Cancer PFS outcomes also produced meaningful gains in overall response rate, complete response rate, and duration of response versus chemotherapy. The safety profile matched known patterns for the PD-1 inhibitor with no new signals, reinforcing the reliability of the efficacy differences. These findings broaden pembrolizumab’s role by supplying the first monotherapy comparison against platinum doublet chemotherapy in dMMR disease.

Market Access Considerations

Health technology assessment bodies may factor the PFS advantage and response durability into economic models evaluating pembrolizumab as a chemotherapy-sparing option for dMMR patients. Ongoing overall survival maturation and parallel development programs will provide further inputs for cost-effectiveness and sequencing decisions. Market strategies can draw on the trial’s eligibility criteria and endpoint structure to support value demonstrations amid rising endometrial cancer incidence.